Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Phase 1/2 Recruiting
980 enrolled
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1/2 Recruiting
250 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Phase 1/2 Recruiting
71 enrolled
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
280 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Phase 1/2 Recruiting
135 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
ODIN
Phase 1/2 Recruiting
43 enrolled
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Phase 1/2 Recruiting
266 enrolled
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Phase 1/2 Recruiting
122 enrolled
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Phase 1/2 Recruiting
170 enrolled
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Phase 1/2 Recruiting
66 enrolled
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase 1/2 Recruiting
112 enrolled
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Phase 1/2 Recruiting
45 enrolled
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Phase 1/2 Recruiting
200 enrolled
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Phase 1/2 Recruiting
61 enrolled
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Phase 1/2 Recruiting
360 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Phase 1/2 Recruiting
110 enrolled
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
Phase 1/2 Recruiting
61 enrolled
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Phase 1/2 Recruiting
130 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Phase 1/2 Recruiting
70 enrolled
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Phase 1/2 Recruiting
300 enrolled
PHANTOM
Phase 1/2 Recruiting
26 enrolled
BRIGHT
Phase 1/2 Recruiting
10 enrolled
ERADIC8
Phase 1/2 Recruiting
120 enrolled
NEO-CLAUD
Phase 1/2 Recruiting
57 enrolled
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Phase 1/2 Recruiting
71 enrolled
T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 1/2 Recruiting
58 enrolled
START-001
Phase 1/2 Recruiting
365 enrolled
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Phase 1/2 Recruiting
40 enrolled
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
115 enrolled
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/2 Recruiting
55 enrolled
QL1706 Combined With SOX Used in Theperioperative Treatment
Phase 1/2 Recruiting
54 enrolled
HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
150 enrolled
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
Phase 1/2 Recruiting
57 enrolled
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Phase 1/2 Recruiting
51 enrolled
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/2 Recruiting
240 enrolled
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
523 enrolled
GC-Ib/II
Phase 1/2 Recruiting
52 enrolled
BAH250
Phase 1/2 Recruiting
75 enrolled
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Phase 1/2 Recruiting
100 enrolled
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/2 Recruiting
167 enrolled
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Phase 1/2 Recruiting
60 enrolled